CC
CGTX icon

Carlson Capital’s Cognition Therapeutics CGTX Stock Holding History

Carlson Capital’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-140,000
Closed -$232K – 17
2024
Q2 		$232K Sell
140,000
-73,995
-35% -$148K 0.04% 91
2024
Q1 		$389K Sell
213,995
-24,005
-10% -$49.6K 0.03% 108
2023
Q4 		$440K Sell
238,000
-52,000
-18% -$68.8K 0.04% 113
2023
Q3 		$418K Buy
290,000
+45,000
+18% +$70.5K 0.03% 125
2023
Q2 		$448K Sell
245,000
-169
-0.1% -$358 0.04% 111
2023
Q1 		$485K Buy
245,169
+15,269
+7% +$29.1K 0.05% 105
2022
Q4 		$483K Buy
229,900
+129,900
+130% +$262K 0.04% 108
2022
Q3 		$190K Buy
+100,000
New +$208K 0.01% 119

Other funds holding CGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Carlson Capital's CGTX Position: Q3 2024 in Review

Carlson Capital sold out of Cognition Therapeutics (CGTX) in Q3 2024, closing a stake of 140,000 shares — an estimated $232K sold.

Carlson Capital first reported a position in CGTX in Q3 2022 and held it in 8 quarters. The position peaked at $485K in Q1 2023. 40 funds tracked by Wall St. Rank hold CGTX as of Q3 2024.

  • Carlson Capital reported no remaining Cognition Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Carlson Capital sold 140,000 Cognition Therapeutics shares in Q3 2024, an estimated $232K.
  • Carlson Capital first reported a position in Cognition Therapeutics in Q3 2022 and held it in 8 quarters.
  • Carlson Capital's Cognition Therapeutics position peaked at $485K in Q1 2023.
  • 40 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2024.

Based on Carlson Capital's 13F filing for Q3 2024, filed 14 Nov 2024.